PharmAust Expands Site Recruitment for Phase II Pet Dog Cancer Trial

By Meagan Evans. Published at Dec 11, 2019, in ASX Biotechs

PharmAust Ltd (ASX:PAA), a clinical-stage oncology company developing targeted cancer therapeutics for humans and animals, reports that it has expanded site recruitment for its anti-cancer trial in pet dogs with treatment naïve B cell lymphoma.

The company’s lead drug candidate is Monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a key driver of cancer.

MPL has been evaluated in Phase 1 clinical trials in both humans and dogs. It was well tolerated and produced a significant reduction in key prognostic biomarkers. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug in Phase 2 clinical trials. MPL is a repurposed drug that’s already approved for veterinary use by Elanco Animal Health.

With the additional participating sites and an associated advertising campaign, PharmAust now expects the pace of recruitment of canine patients to be increased.

In conjunction with the trial manager, U-Vet in Werribee, and through the University of Melbourne’s Department of Veterinary Clinical Sciences, PharmAust has now also contracted the University Veterinary Teaching Hospital at the University of Sydney (UVTHS) as well as the West Australian Veterinary Emergency and Specialists (WAVES) in Perth.

The UVTHS site will be run by Dr Peter Bennett and the WAVES site will be run by Dr Sue Bennett (no relation). Dr Peter Bennett is one of Australia’s leading cancer clinical trial specialists and both sites are highly acknowledged and recognised for their work in treating veterinary cancer.

With the addition of these two sites, PharmAust now has central referral sites within Victoria, New South Wales (two including the previously announced Animal Referral Hospital in Homebush, Sydney) and Western Australia.

The company anticipate this national network to facilitate and expedite the generation of meaningful and successful outcomes for this trial.

In further supporting this network and expediting recruitment, PharmAust has also engaged a pet journalist and has commenced an aggressive marketing awareness campaign to vets and pet owners.

PharmAust’s Chief Scientific Officer Dr Richard Mollard stated: “PharmAust is pleased and excited to have the support and involvement of Dr Peter Bennett and Dr Sue Bennett. Having the participation of such highly accredited veterinarians and hospitals is a tribute to the diligent preclinical and clinical work PharmAust has executed preparing monepantel for re-entry into the clinic for this pivotal trial. PharmAust is looking forward to reporting meaningful and successful outcomes to the market.”

View Our Investment Portfolios

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why is Australia’s leading small cap publication

Founded seven years ago, is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise. provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more. is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!